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Abstract
Inflammatory mediators are involved in the pathogenesis of airway inflammation, but the role of
prostaglandin I2 (PGI2) remains obscure. This study was designed to investigate the role of PGI2
in cough reflex sensitivity of the asthmatic airway, which is characterized by chronic eosinophilic
airway inflammation. The effect of beraprost, a chemically and biologically stable analogue of PGI2,
on cough response to inhaled capsaicin was examined in 21 patients with stable asthma in a
randomized, placebo-controlled cross over study. Capsaicin cough threshold, defined as the lowest
concentration of capsaicin eliciting five or more coughs, was measured as an index of airway cough
reflex sensitivity. The cough threshold was significantly (p < 0.05) decreased after two weeks of
treatment with beraprost [17.8 (GSEM 1.20) μM] compared with placebo [30.3 (GSEM 1.21) μM].
PGI2 increases cough reflex sensitivity of the asthmatic airway, suggesting that inhibition of PGI2
may be a novel therapeutic option for patients with asthma, especially cough predominant asthma.
Background
Chronic cough is one of the commonest respiratory symp-
toms. Cough has been considered to be a defense mecha-
nism of the airway to remove irritant particles or excess
mucus, whereas non-productive cough, which is not asso-
ciated with the clearance of the tracheobronchial mucus,
may occur via increased cough reflex sensitivity. Inflam-
matory mediators such as prostaglandins may adjust the
cough reflex sensitivity. However, little is known about
how cough reflex sensitivity is influenced by airway
inflammatory processes. Although our previous study has
clearly shown that arachidonate cyclooxygenase products
can modulate airway cough reflex sensitivity to inhaled
capsaicin [1], the effects of other mediators remains
unknown.
It has been recognized that prostaglandin I2 (PGI2, pros-
tacyclin) is the most abundant prostanoid generated on
IgE-dependent challenge of human lung tissue in vitro
[2,3]. Others reported that alveolar macrophages are able
to synthesize large amount of PGI2 [4]. These findings
indicate that PGI2 may play some role in the asthmatic
airway and can affect airway cough reflex sensitivity. This
study was conducted to elucidate this hypothesis. We
investigated the effect of oral administration of beraprost,
a chemically and biologically stable analog of PGI2
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{sodium (±)-4[(1R, 2R, 3aS, 8bS)-1, 2, 3a, 8b-tetrahydro-
2-hydroxyl 2[(3S, 4RS)-3-hydroxy-4-methyl-oct-6-yne-
(E)-l-enyl]-5-cyclopenta [b] benzofuranyl] butyrate}, on
cough reflex sensitivity to inhaled capsaicin in patients
with stable asthma [5].
Subjects and Methods
Subjects
Twenty-one patients with bronchial asthma (12 males
and 9 females) with a mean age of 73.2 ± 1.5 (± SEM)
(range 54–83) yrs participated in this study. All patients
were lifetime nonsmokers or ex-smokers with no history
of viral infection for at least 4 weeks prior to the study.
Characteristics of individual patients are shown in Table
1. Informed consent was obtained from all subjects. This
study was approved by the Ethics Committee of our hos-
pital.
Each asthmatic patient satisfied the American Thoracic
Society definition of asthma, with symptoms of episodic
wheezing, cough, and shortness of breath responding to
bronchodilators, and reversible airflow obstruction docu-
mented on at least one previous pulmonary function
study [6]. Reversibility was defined as greater than 12 %
and 200 ml increase in the forced expiratory volume in
one second (FEV1) following a bronchodilator inhalation
(Table 1). All patients had bronchial hyperresponsiveness
as shown in Table 1. Classification of asthma severity was
defined according to Global Strategy for Asthma Manage-
ment and Prevention. Patients with atopy were recognized
as having a hereditary tendency to produce IgE antibodies
against common environmental allergens [7]. This study
was carried out when symptoms were mild and stable,
while patients were taking oral theophylline, oral (short-
acting clenbuterol) and/or aerosol β2-agonists (short-act-
ing procaterol), inhaled steroids (beclomethasone dipro-
pionate), inhaled anti-cholinergic agents (oxitropium
bromide) and/or mucolytic agents (carbocysteine)
according to previous reports [8-10]. They had not
received oral steroids for at least eight weeks.
Assessment of cough reflex sensitivity to inhaled capsaicin
Cough reflex sensitivity was assessed by capsaicin provo-
cation test [11]. Capsaicin (30.5 mg) was dissolved in
Tween 80 (1 mL) and ethanol (1 mL) and then dissolved
in physiological saline (8 mL) to make a stock solution of
Table 1: Clinical characteristics of patients
Patient 
number
Age 
(yr)
Sex Height 
(cm)
Type Severity Total IgE 
in serum 
(IU/ml)
Specific 
IgE in 
serum
Complicati
on of 
allergic 
disease
PC20-FEV1 
(mg/ml)*
Bronchodi
lator 
response 
(%)**
Treatment
BDP 
(μg/day)
Theophylline 
(mg/day)
Clenbuterol 
(μg/day)
Carbocysteine 
(mg/day)
1 54 M 161 Int Moderate 420 - - 2.5 15.2 800 400 40 0
2 72 F 147 Ext Moderate 642 Mite, HD AR 0.31 31.5 800 400 0 0
3 70 M 161 Ext Mild 312 Mite, HD, 
Cedar
- 0.08 20.2 0 600 0 0
4 71 F 140 Int Mild 17 - - 1.25 17.6 800 0 0 0
5 83 M 154 Ext Moderate 345 Mite, HD, 
Cedar
- 5 17.1 800 400 40 1500
6 71 M 165 Ext Moderate 146 Mite, HD AR 1.25 15.6 0 0 40 0
7 77 F 144 Int Mild 51 - - 0.31 17.9 0 0 0 1500
8 71 M 155 Int Mild 42 - - 2.5 29.4 800 0 0 1500
9 80 M 152 Int Moderate 66 - - 1.25 39 800 0 0 0
10 75 M 162 Ext Mild 143 Candida - 2.5 14.1 800 0 0 0
11 80 F 145 Ext Mild 3 HD, 
Cedar
-0 . 0 8 3 7 . 1 8 0 0 0 0 0
12 63 F 154 Ext Moderate 77 Cedar AR 1.25 14.7 800 0 0 0
13 77 F 142 Int Mild 105 - - 5 17 0 400 20 0
14 70 M 155 Int Moderate 82 - - 0.31 15.4 800 0 0 1500
15 70 F 151 Ext Mild 467 Mite, HD - 2.5 20.4 800 400 40 0
16 72 F 150 Int Mild 57 - - 5 22.3 600 0 0 1500
17 81 M 163 Int Moderate 64 - - 0.31 33.4 800 600 40 1500
18 71 M 150 Int Moderate 107 - - 5 16.4 800 400 40 0
19 80 M 160 Int Mild 87 - - 2.5 29.5 0 400 0 0
20 68 M 167 Ext Mild 264 Cedar - 5 27 0 400 40 0
21 80 F 152 Int Mild 54 - - 2.5 17.3 0 400 0 0
Ext, extrinsic; Int. Intrinsic; HD, house dust; AR, allergic rhinitis; UR, urticaria; BDP, beclomethasone diproprionate inhalation.
* PC20-FEV1 shows concentration of inhaled methacholine causing a 20% fall in FEV1.
** Bronchodilator response means percent increase in forced expiratory volume in 1s (FEV1) from the baseline value after inhalation of 300 μg of 
salbutamol sulfate.
All patients used inhaled β2-agonists (salbutamol or procaterol) on demand.Cough 2007, 3:2 http://www.coughjournal.com/content/3/1/2
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1 × 10-2 M, which was stored at -20°C. This solution was
diluted with physiological saline to make solutions start-
ing at a concentration of 0.49 μM and increasing it by
doubling concentrations up to 1000 μM. Each subject
inhaled a control solution of physiological saline fol-
lowed by progressively increasing concentrations of the
capsaicin solution. Solutions were inhaled for 15 s every
60 s, by tidal mouth-breathing wearing a noseclip from a
Bennett Twin nebulizer (3012-60 cc, Puritan-Bennett Co.,
Carlsbad, California, USA). Increasing concentrations
were inhaled until five or more coughs were elicited. The
nebulizer output was 0.21 mL/min. The number of capsa-
icin-induced coughs was counted by a blinded medical
technician in our pulmonary function laboratory. The
cough threshold was defined as the lowest concentration
of capsaicin that elicited five or more coughs.
Study protocol (Figure 1)
The medication was stopped at 9.00 p.m. on the previous
day to allow a washout time of 12 h or more before the
measurement of cough threshold to inhaled capsaicin at
10.00 a.m. on each test day to reduce the diurnal variabil-
ity of the cough response.
Each patient attended 4 times separated by 2 weeks, at the
same time each day. Control measurement of capsaicin
cough threshold was carried out 2 weeks before initiation
of the first treatment (run-in). Two weeks treatment with
beraprost sodium or placebo was performed separated by
a two-week washout period in a randomized, cross-over
fashion. Two beraprost sodium tablets (40 μg) and their
placebo were taken orally three times a day for 14 days
and at 8.00 a.m. on the test day. FEV1 was measured on a
dry wedge spirometer (Transfer Test, P.K. Morgan Ltd.,
UK) before capsaicin challenge to assess the bronchoac-
tive effect of the treatment regimens. Serum total IgE levels
and the number of peripheral eosinophils were measured
to assess anti-allergic effect of the test drugs.
Data analysis
Capsaicin cough threshold values were expressed as geo-
metric mean with geometric standard error of the mean
(GSEM). Forced vital capacity (FVC), FEV1 and maximal
mid expiratory flow (MMF) were shown as arithmetic
mean values ± SEM. The FVC values, the FEV1 values and
the MMF values were compared between each pair of the
four groups (run-in, washout, beraprost sodium and pla-
cebo) by the Wilcoxon signed-ranks test. A p-value of 0.05
or less was taken as significant.
Results
Cough threshold to inhaled capsaicin before each treat-
ment (run-in, washout) and after treatment with berap-
rost and placebo are shown in Figure 2. Geometric mean
values for the cough threshold were 29.5 (GSEM 1.17) μM
in the run-in period, 26.5 (GSEM 1.18) μM in the wash-
out period, 17.8 (GSEM 1.20) μM after beraprost treat-
ment and 30.3 (GSEM 1.21) μM after placebo treatment.
Study protocol Figure 1
Study protocol.Cough 2007, 3:2 http://www.coughjournal.com/content/3/1/2
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The cough threshold after the beraprost treatment was sig-
nificantly (p < 0.05) lower than the value after the placebo
treatment. FVC, FEV1 or MMF value was not significantly
different between run-in period, washout period, berap-
rost treatment and placebo treatment as shown in Table 2.
Figure 3 and figure 4 show the changes in serum IgE and
peripheral blood eosinophils, respectively. Treatment
with beraprost did not affect the IgE production or periph-
eral blood eosinophil count.
Discussion
The present study showed that two-week treatment with a
stable PGI2 analogue, beraprost, decreased the cough
threshold to inhaled capsaicin in asthmatic patients. No
difference could be found in the baseline pulmonary
function, IgE production or peripheral eosinophil count
between beraprost and placebo treatments. These findings
suggest that PGI2 enhances the cough reflex sensitivity in
the asthmatic airway.
Cough is one of the main symptoms of bronchial asthma
which can profoundly and adversely affect the quality of
patient's lives and social activities, whereas the mecha-
nisms underlying the cough remain obscure. Previous
researchers [12] indicated that cough receptors are stimu-
lated by local bronchoconstriction. This finding may be
one of the causes of cough in bronchial asthma. However,
recent studies about cough variant asthma (CVA) revealed
normal baseline pulmonary function and mild bronchial
hyperresponsiveness [13,14]. Our previous study has also
demonstrated that inhaled procaterol in a dose sufficient
to produce bronchodilation has no effect on airway cough
receptor sensitivity in asthma [15]. O'Connell and col-
leagues have reported that cough reflex sensitivity is
increased in some asthmatic patients suffering from daily
coughing and recovers to normal range after relief of the
cough on treatment [16]. These findings suggest that
cough reflex hypersensitivity is another mechanism of
chronic non-productive cough in asthma, in addition to
cough receptor stimulation by local bronchoconstriction
[12].
It has been revealed that inflammatory mediators such as
arachidonate metabolites play major roles in the patho-
genesis of bronchial asthma, however, the relationship
between inflammatory mediators and airway cough reflex
sensitivity remains obscure. Some studies indicated that
some inflammatory mediators might modulate the sensi-
tivity of cough reflex [1,17]. We showed that intrinsic
thromboxane A2 (TxA2) is a possible modulator aug-
menting both airway cough reflex sensitivity and bron-
chial responsiveness while it does not have
bronchoconstricting effect in stable asthmatics [1,18,19].
Other researchers reported that prostaglandin F2α
(PGF2α) enhances airway cough reflex sensitivity with
bronchoconstricting effect [2,20]. It has been also shown
that inhaled prostaglandin E2 (PGE2), which acts as a
bronchodilator, enhances cough reflex sensitivity [20,21].
Although cysteinyl leukotrienes (cLTs) play an important
role in bronchomotor tone of the asthmatic airway, their
role in cough reflex sensitivity is controversial [19,22].
These findings indicate that arachidonate metabolites
including prostaglandins may have variable roles in the
local control of the cough reflex with no relation to bron-
choconstriction.
It has been known that PGI2 is the most abundant prosta-
noid generated on IgE-dependent challenge of human
lung tissue in vitro [2,3]. Others reported that alveolar
macrophages are able to synthesize a large amount of
PGI2 [4]. These findings imply that PGI2 plays some role
in asthmatic airway. Although PGI2 causes relaxation of
isolated precontracted human bronchus [23], its clinical
effect is limited: short-term protection against immediate
bronchoconstriction provoked by exercise [24], and neb-
ulized distilled water [24] but not by allergen [25] or aspi-
rin [26]. Therefore, the exact role of PGI2 in asthmatic
airway remains obscure. Hardy et al. reported an irritative
effect of single inhalation of PGI2 on human airways [27],
but influence of repeated administration has not been
studied. Szczeklik and their colleagues also reported that
four out of twelve asthmatic patients complained of
coughing during PGI2 inhalation [28]. However, these
previous reports have not investigated the change of
cough reflex sensitivity. Thus the exact role of PGI2 in air-
way cough reflex sensitivity also remains unknown. We
observed that some patients complained of coughing on
treatment with beraprost but none did with placebo. The
implication of this study is that PGI2 may be involved in
the pathogenesis of cough reflex sensitivity rather than
Table 2: Pulmonary function on beraprost and placebo treatments in patients with bronchial asthma
Run-in Placebo Washout Beraprost
FVC as % pred. (%) 96.8 ± 5.7 103.4 ± 3.3 104.4 ± 3.1 103.4 ± 3.4
FEV1 as% pred. (%) 90.9 ± 5.7 94.1 ± 5.5 93.0 ± 5.6 93.2 ± 5.6
MMF as% pred. (%) 50.7 ± 6.7 52.0 ± 6.0 50.1 ± 6.4 51.5 ± 6.4
Data are shown as standard error of the mean for FVC, FEV1 and MMF.
* p < 0.05 compared with each control value (Wilcoxon signed-ranks test).Cough 2007, 3:2 http://www.coughjournal.com/content/3/1/2
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Individual data of serum IgE at run-in period, at washout period and on treatment with beraprost and placebo in patients with  stable bronchial asthma Figure 3
Individual data of serum IgE at run-in period, at washout period and on treatment with beraprost and placebo in patients with 
stable bronchial asthma. Each horizontal bar represents geometric mean value. Closed circles and open circles represent 
patients undergoing steroid inhalation therapy and patients without steroid inhalation therapy, respectively. P values: Wilcoxon 
signed-ranks test using logarithmically transformed values.
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Individual data of capsaicin cough threshold at run-in period, at washout period and on treatment with beraprost and placebo  in patients with stable bronchial asthma Figure 2
Individual data of capsaicin cough threshold at run-in period, at washout period and on treatment with beraprost and placebo 
in patients with stable bronchial asthma. Each horizontal bar represents geometric mean value. Closed circles and open circles 
represent patients undergoing steroid inhalation therapy and patients without steroid inhalation therapy, respectively. P values: 
Wilcoxon signed-ranks test using logarithmically transformed values.Cough 2007, 3:2 http://www.coughjournal.com/content/3/1/2
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bronchodilation and it may explain the role of PGI2 in the
asthmatic airway which has been unknown so far.
Overall, our data support the conclusion that inhibition
of PGI2 formation or action may be a novel treatment for
chronic non-productive cough in asthmatic airway, espe-
cially in cough variant asthma or cough predominant
asthma with normal baseline pulmonary function. This is
the first report demonstrating the role of PGI2 in cough
reflex sensitivity in the asthmatic airway. Further studies
may be required to elucidate the role of PGI2 in other
eosinophilic bronchial disorders presenting with non-
productive cough with normal baseline pulmonary func-
tions [29-31].
Abbreviations
cLT = cysteinyl leukotriene; CVA = cough variant asthma;
FEV1 = forced expiratory volume in one second; FVC =
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